CDT Equity restates Q1 2025 financials; $0.4M milestone misclassified as R&D

CDT Equity Inc.

On Aug 8, 2025, CDT Equity determined its unaudited Q1 2025 financials should no longer be relied upon.
$0.4 million in milestone payments to Sarborg Limited were misclassified as R&D expense instead of an acquired diagnostic asset.
The restatement requires amendments to the Q1 2025 10-Q, affecting balance sheet, income statement, and cash flows.
The Audit Committee and independent accounting firm CBIZ CPAs agreed on the restatement.

item 4.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.